Management of Telemedicine Monitoring of Patients With Chronic Heart Failure
NCT ID: NCT05885425
Last Updated: 2023-06-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2023-09-01
2024-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Patients with a stable form of congestive heart failure will be gradually included in the study. Half of them will be defined by random selection to intervention group. Parameters, that can be measured at home will be periodically telemedical monitored. In according with at home monitored data, the own physician will be able to intervene with change of medical treatment in the case of non-physiological deviations in order to improve the health status as well as the prognosis of the patient with CHF.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multiparametric Telemonitoring In Elderly People With Chronic Heart Failure
NCT01914588
Effectiveness of a Cardiac Telerehabilitation Program in Chronic Heart Failure
NCT07023536
Telemedicine in Heart Failure; Treatment, Prognosis and Patient Experience
NCT06237998
CHF Management Using Telemedicine
NCT00309764
The TElemonitoring in the Management of Heart Failure (TEMA-HF) 1 Long-term Follow-up Study
NCT03171038
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Age between 45 and 75
* Congestive heart failure (CHF), NYHA II - VI (any genesis)
* EF less then 45%, any rhythm (sinus or atrial fibrillation)
* More as two months stable condition
* Complete treatment according to recommendations (guidelines): ACEI (alternatively ARNI / sartan) + diuretics + betablockers (as alternative digitalis)
* Without hospitalization with CHF decompensation more as two months before enrolment
* No severe liver disease and hemodialysis treatment
* No planned any cardio-surgery intervention in the next six months
* No a serious valvular defects
Input and output surveys (measurements, tests) upon enrollment and after half a year ECHOCG (mandatory parameters: EF, LVDd, IVCT, E/A, LA diameter, LA area planimetrically) Blod pressure, frequency, ECG (PQ, QT, description: blockages, STT segment changes) Six minutes walking test Serum analysis: NTproBNP, CRP, natrium, potassium, urea, creatinine
Questionnaires:
* Kansas Quality of Life Questionnaire (KCCQ)
* Questionnaire SF 36 (perception of illness)
* Beck's Depression Inventory (21 questions) - depression questionnaire
* Beck's Anxiety Inventory (21 questions) - anxiety questionnaire (standardized questionnaires translated into Slovak)
Telemedicine monitoring: the patient will have at home devices for:
ECG recording Blood pressure and pulse sensor O2 saturation sensor Personal weight machine
Data will be transferred via smartphone software (supplied by the organizer) once a week too physician:
ECG recording on the patient's instructions
1. st morning in bed after waking up (stick electrodes for whole day)
2. nd. after breakfast (or an hour after getting out of bed)
3. th. around 12 o'clock (time of lunch)
In the same day morning, weight and other measurements (O2, blood pressure, pulse)
As part of the data transfer, the information for physician:
possibility to send a comment "how I feel" the number of urinations per night Data is entered into a standard table in the doctor's software (supplied by the organizer) Based on the obtained data, the doctor can correct the treatment at any time by telephone
Physician will control the transferred data from patient at least once every week.
The organizer will deliver Personal weight machine (new uniform) Questionnaires (in printed form) Informed consents devices for monitoring of physiological functions (ECG, O2, pulse, blood pressure) Application for the patient's smartphone (for simple data transfer) Software recording data from the patient to the PC at the physician's office Compensation 100,- € (motivation for each participant - intervened or non-intervened) similar compensation is assumed at the end of follow-up (for each patient) The ECG sensor will remain available to the physicians Included doctors will be co-authors of publications in foreign journals.
Monitored events ("end points"):
hospitalization for cardiac causes visit to the emergency room (urgent) calling Quick Medical Assistance at home unplanned visit by cardiologist / internist fundamental change of treatment (new type of drug, change of drug group, increased dose) fundamental changes (deterioration) in the perception of the disease (SF 36) major changes in quality of life (Kansas Questionnaire) fundamental changes in the perception of depression (Beck's Depression Inventory) fundamental changes in the perception of anxiety (Beck's Anxiety Inventory) Death
Evaluation in addition to endpoints:
long-term trend of resting frequency long-term trend of increased frequency after morning exercise and during the day long-term blood pressure and saturation trends number of telephone contacts by physicians with the patient in the case of using a "smart watch", also trends in sleep parameters (frequency, apnea, sleep quality, caloric expenditure / day)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
100 patients with stabile chronic heart failure with remote control
Group 1 is the intervention group, their health status will be monitored telemetrically for a half year by several electronic devices (for measurement of hearth frequency, blood pressure, blood saturation and periodically ECG recordings). Data will be periodically transmitted to the doctor in the ambulance. If measured data will indicated any worsening of heath (decompensation of circulation), physician will adjust the treatment remotely.
Telemedicine correction of medical treatment
On the basis of telemedicine data, the doctor will remotely correct medical treatment by adjusting the dose or supplementing or by omitting the medicine in order to improve the state of health, or to alleviate the symptoms of the disease monitored by telemedicine
Education for proper lifestyle
Based on telemedicine data, the doctor can consider periodic education of the patient with the innervated group in order to improve lifestyle
Non-intervention group: 100 patients with stabile chronic heart failure without remote control
Group 2 with patients with chronic heart failure in the non-intervention group, they will not be contacted by own physician for half a year - the planned periodic control will be scheduled after half a year.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Telemedicine correction of medical treatment
On the basis of telemedicine data, the doctor will remotely correct medical treatment by adjusting the dose or supplementing or by omitting the medicine in order to improve the state of health, or to alleviate the symptoms of the disease monitored by telemedicine
Education for proper lifestyle
Based on telemedicine data, the doctor can consider periodic education of the patient with the innervated group in order to improve lifestyle
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* EF less then 45%, any rhythm (sinus or atrial fibrillation)
* More as two months stable condition
* Complete treatment according to recommendations (guidelines): ACEI (alternatively ARNI / sartan) + diuretics + betablockers (as alternative digitalis)
* Without hospitalization with CHF decompensation more as two months before enrolment
Exclusion Criteria
* planned cardiac surgery
45 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Trnava University in Trnava
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eva Goncalvesova
Role: PRINCIPAL_INVESTIGATOR
National Institute of Vascular and Heart Diseases Bratislava
Fedor Lehocki
Role: STUDY_CHAIR
Slovak University of Technology in Bratislava
Jozef Benacka
Role: STUDY_DIRECTOR
Trnava University in Trnava
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OPII-VA/DP/2021/9.3-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.